Key Takeaways
STAAR Surgical introduced the FDA-approved EVO Visian Implantable Collamer Lens (EVO ICL) in the USA in March 2022. To be clear, this is not a new technology as a million recipients have received it globally. ICL's have been successfully implanted since 1993, but what makes the EVO ICL unique is that this lens removes a once necessary step prior to surgery, the need for a peripheral iridotomy (YAG PI) which was needed to perforate the iris. The EVO ICL has a central lens perforation that does not impact the lens optics and allows the flow of aqueous fluid around the lens and anterior eye chamber without anatomically altering the iris. This is a long-awaited technology.
The EVO Visian ICL is a biocompatible implantable lens designed to be used in phakic eye treatment for patients ages 21 to 45 with mild to severe myopia (-3D to -20D). EVO ICL is a viable and sometimes, only surgical vision correction option, for patients not suitable candidates for LASIK. Unlike LASIK, the EVO lens can be implanted in a reasonably quick surgical procedure lasting about 15 minutes per eye involving no removal of corneal tissue. Furthermore, the lens is removable by a surgeon. Patients seeking visual freedom with thin corneas and not ideal LASIK candidates can still enjoy a physically active lifestyle and find solace in this effective EVO ICL technology that provides UV protection and ease of living.
Interested In EVO Visian ICL Technology In San Antonio?
At San Antonio Eye Specialists, our very own Dr. Iskander is one of the first doctors in the state of Texas to utilize EVO Visian ICL Technology. Want to learn more or to schedule an appointment? Give us a call or contact us online today! For your eyes... don't compromise!